NASDAQ:PETX - Aratana Therapeutics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.92
+0.30 (1.20%)
Get New Aratana Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PETX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PETX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Aratana Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $4.92.
N/A
The current consensus among 0 investment analysts is to n/a stock in Aratana Therapeutics. This rating has held steady since April 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/30/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$4.76Low
i
4/26/2019HC WainwrightDowngradeBuy ➝ Neutral$5.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/24/2019William BlairDowngradeOutperform ➝ Market Perform$4.14Medium
i
Rating by J. Kreger at William Blair
1/11/2019Stifel NicolausDowngradeBuy ➝ Hold$8.00 ➝ $5.00High
i
11/5/2018HC WainwrightSet Price TargetBuy$10.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/6/2018Stifel NicolausLower Price TargetBuy ➝ Buy$8.00 ➝ $7.00High
i
5/7/2018HC WainwrightSet Price TargetBuy$10.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/27/2018Stifel NicolausUpgradeHold ➝ Buy$6.00 ➝ $8.00High
i
3/19/2018HC WainwrightSet Price TargetBuy$10.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/16/2018Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$9.00 ➝ $8.00Low
i
3/12/2018CL KingUpgradeNeutral ➝ Buy$8.00High
i
Rating by David Westenberg at CL King
1/16/2018HC WainwrightSet Price TargetBuy$10.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/27/2017CL KingInitiated CoverageNeutral ➝ NeutralLow
i
12/21/2017HC WainwrightSet Price TargetBuy$10.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/18/2017Stifel NicolausReiterated RatingHold$6.00High
i
11/17/2017HC WainwrightInitiated CoverageBuy ➝ Buy$10.00N/A
i
Rating by S. Ramakanth at HC Wainwright
11/16/2017Jefferies Financial GroupSet Price TargetBuy$9.00N/A
i
Rating by David Gu at Jefferies Financial Group Inc.
11/3/2017Jefferies Financial GroupReiterated RatingBuy$8.00N/A
i
Rating by David Gu at Jefferies Financial Group Inc.
8/25/2017Lake Street CapitalLower Price TargetBuy ➝ Buy$15.00 ➝ $10.00Low
i
8/4/2017Jefferies Financial GroupSet Price TargetBuy$8.00High
i
Rating by David Gu at Jefferies Financial Group Inc.
6/8/2017Jefferies Financial GroupSet Price TargetBuy$8.00Medium
i
Rating by David Gu at Jefferies Financial Group Inc.
5/14/2017Jefferies Financial GroupReiterated RatingBuy$8.00Medium
i
Rating by David Gu at Jefferies Financial Group Inc.
5/10/2017Stifel NicolausLower Price TargetBuy ➝ Buy$8.00 ➝ $7.00Low
i
5/5/2017Jefferies Financial GroupReiterated RatingBuy$8.00High
i
Rating by David Gu at Jefferies Financial Group Inc.
3/16/2017Jefferies Financial GroupLower Price Target$8.00Low
i
Rating by David Gu at Jefferies Financial Group Inc.
3/14/2017Jefferies Financial GroupSet Price TargetBuy$11.00Low
i
Rating by David Gu at Jefferies Financial Group Inc.
2/9/2017William BlairReiterated RatingOutperformN/A
i
2/6/2017Stifel NicolausDowngradeBuy ➝ Hold$8.00N/A
i
11/18/2016Jefferies Financial GroupReiterated RatingBuy$13.00 ➝ $11.00N/A
i
Rating by david gu at Jefferies Financial Group Inc.
9/6/2016Lake Street CapitalReiterated RatingBuy$15.00N/A
i
Rating by Carl Byrnes at Lake Street Capital
8/19/2016Jefferies Financial GroupInitiated CoverageBuy$12.00 ➝ $13.00N/A
i
Rating by Jeffrey Holford at Jefferies Financial Group Inc.
8/17/2016William BlairReiterated RatingOutperformN/A
i
8/11/2016BarclaysLower Price TargetOverweight$15.00 ➝ $11.00N/A
i
8/10/2016Credit Suisse GroupReiterated RatingBuy$11.00N/A
i
Rating by Erin Wilson at Credit Suisse Group AG
7/17/2016Lake Street CapitalReiterated RatingBuy$15.00N/A
i
Rating by Carl Byrnes at Lake Street Capital
4/26/2016William BlairReiterated RatingOutperformN/A
i
(Data available from 4/21/2016 forward)
Aratana Therapeutics logo
Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.
Read More

Today's Range

Now: $4.92
$4.92
$4.92

50 Day Range

MA: $4.92
$4.92
$4.92

52 Week Range

Now: $4.92
$3.30
$7.16

Volume

N/A

Average Volume

1,030,946 shs

Market Capitalization

$241.08 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Frequently Asked Questions

What sell-side analysts currently cover shares of Aratana Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Aratana Therapeutics in the last year:
View the latest analyst ratings for PETX.

What is the current price target for Aratana Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Aratana Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Aratana Therapeutics in the next year.
View the latest price targets for PETX.

What is the current consensus analyst rating for Aratana Therapeutics?

Aratana Therapeutics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PETX.

What other companies compete with Aratana Therapeutics?

How do I contact Aratana Therapeutics' investor relations team?

Aratana Therapeutics' physical mailing address is 11400 TOMAHAWK CREEK PARKWAY SUITE 340, LEAWOOD KS, 66211. The biopharmaceutical company's listed phone number is 913-353-1000 and its investor relations email address is [email protected] The official website for Aratana Therapeutics is www.aratana.com.